These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 28300466)

  • 61. A two-stage dose selection strategy in phase I trials with wide dose ranges.
    Wang O; Faries DE
    J Biopharm Stat; 2000 Aug; 10(3):319-33. PubMed ID: 10959914
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A web tool for designing and conducting phase I trials using the continual reassessment method.
    Wages NA; Petroni GR
    BMC Cancer; 2018 Feb; 18(1):133. PubMed ID: 29402249
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The continual reassessment method for multiple toxicity grades: a bayesian model selection approach.
    Pan H; Zhu C; Zhang F; Yuan Y; Zhang S; Zhang W; Li C; Wang L; Xia J
    PLoS One; 2014; 9(5):e98147. PubMed ID: 24875783
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Toxicity equivalence range design (TEQR): a practical Phase I design.
    Blanchard MS; Longmate JA
    Contemp Clin Trials; 2011 Jan; 32(1):114-21. PubMed ID: 20923709
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.
    Paoletti X; Kramar A
    Stat Med; 2009 Oct; 28(24):3012-28. PubMed ID: 19672839
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Optimal dose escalation methods using deep reinforcement learning in phase I oncology trials.
    Matsuura K; Sakamaki K; Honda J; Sozu T
    J Biopharm Stat; 2023 Sep; 33(5):639-652. PubMed ID: 36717962
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Hierarchical models for sharing information across populations in phase I dose-escalation studies.
    Cunanan KM; Koopmeiners JS
    Stat Methods Med Res; 2018 Nov; 27(11):3447-3459. PubMed ID: 28480828
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Sensitivity of dose-finding studies to observation errors.
    Zohar S; O'Quigley J
    Contemp Clin Trials; 2009 Nov; 30(6):523-30. PubMed ID: 19580886
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Quasi-partial order continual reassessment method: Applying toxicity scores to cancer dose-finding drug combination trials.
    O'Connell NS; Wages NA; Garrett-Mayer E
    Contemp Clin Trials; 2023 Feb; 125():107050. PubMed ID: 36529437
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A two-stage algorithm for designing phase I cancer clinical trials for two new molecular entities.
    Su Z
    Contemp Clin Trials; 2010 Jan; 31(1):105-7. PubMed ID: 19879974
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancer.
    Potter DM
    Stat Med; 2002 Jul; 21(13):1805-23. PubMed ID: 12111891
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comparison of design methods for a safety run-in phase of a phase II clinical trial.
    Ji L; Alonzo TA
    Clin Trials; 2023 Apr; 20(2):181-191. PubMed ID: 36628921
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Extending the Continual Reassessment Method to accommodate step-up dosing in Phase I trials.
    Braun TM; Mercier F
    Stat Med; 2022 Sep; 41(20):3975-3990. PubMed ID: 35662077
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Determining a maximum tolerated cumulative dose: dose reassignment within the TITE-CRM.
    Braun TM; Levine JE; Ferrara JL
    Control Clin Trials; 2003 Dec; 24(6):669-81. PubMed ID: 14662273
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A Continual Reassessment Method With Cohort Size Adaptation Based on Bayesian Posterior Probabilities in Phase I Dose-Finding Studies.
    Kakizume T; Morita S
    Ther Innov Regul Sci; 2014 Mar; 48(2):213-219. PubMed ID: 30227515
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Practical modifications of the continual reassessment method for phase I cancer clinical trials.
    Faries D
    J Biopharm Stat; 1994 Jul; 4(2):147-64. PubMed ID: 7951271
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A novel model of the continual reassessment method in Phase I trial.
    Zhang W; Lei W; Zhu X
    Sci Rep; 2023 Mar; 13(1):5047. PubMed ID: 36977709
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials.
    Iasonos A; Gounder M; Spriggs DR; Gerecitano JF; Hyman DM; Zohar S; O'Quigley J
    Clin Cancer Res; 2012 Oct; 18(19):5179-87. PubMed ID: 22825582
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Fractional dose-finding methods with late-onset toxicity in phase I clinical trials.
    Yin G; Zheng S; Xu J
    J Biopharm Stat; 2013; 23(4):856-70. PubMed ID: 23786314
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Isotonic designs for phase I cancer clinical trials with multiple risk groups.
    Yuan Z; Chappell R
    Clin Trials; 2004; 1(6):499-508. PubMed ID: 16279290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.